Browsing by Author "Al-mahallawi, Abdulaziz Mohsen"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Enhanced ocular delivery of clotrimazole via loading into mucoadhesive microemulsion system: In vitro characterization and in vivo assessment
    (Elsevier, 05/02/2021) Al-mahallawi, Abdulaziz Mohsen; Ahmed, Doaa; Hassan, Mariam; El- Setouhy, Doaa Ahmed
    This work aimed to formulate clotrimazole (CLZ), a water-insoluble antifungal drug, into a chitosan-coated microemulsion system for achieving enhanced ocular delivery. In this study, CLZ loaded microemulsions were firstly prepared according to 22 × 31 full factorial design in order to investigate the influence of different formulation variables on microemulsion properties. The selected microemulsion formulation (F4: oleic acid, Cremophor EL: Transcutol HP (1:1) and water (20, 70 and 10%, w/w, respectively)) showed nanosized spherical globules with a droplet size of 229.1 ± 0.989 nm, polydispersity index of 0.5085 ± 0.0095, and zeta potential of − 33.3 ± 0.98 mV. The selected microemulsion was then coated with low molecular weight chitosan to increase the contact time with the eye surface. In vivo studies in albino rabbits demonstrated the superiority of chitosan- coated microemulsion over the uncoated microemulsion and drug suspension formulation concerning sustain- ment of antifungal activity over the eye surface. Moreover, the in vivo, ocular tolerance and histopathological studies conducted using male albino rabbits proved the safety of the prepared microemulsions after topical ocular application. Generally, the obtained results confirmed that CLZ chitosan-coated microemulsion could be promising for ocular CLZ delivery.
  • Thumbnail Image
    Item
    Potential therapeutic and pharmacological strategies for SARS-CoV2
    (Springer, 03/05/2021) Ghareeb, Doaa A; Saleh, Samar R; Nofal, Mohammed S; Kaddah, Mohamed M. Y; Hassan, Salma. F; Seif, Inas K; El-Zahaby, Sally A; Khedr, Shaimaa M; Kenawy, Marwa Y; Masoud, Aliaa A; Soudi, Salma A; Sobhy, Ahmed A; Sery, Jaillan G; Abd El-Wahab, Miral G; Abd Elmoneam, Alshimaa A; Al-mahallawi, Abdulaziz Mohsen; El-Demellawy, Maha A
    Background At the end of 2019, the new Coronavirus disease 2019 (COVID-19) strain causing severe acute respiratory syndrome swept the world. From November 2019 till February 2021, this virus infected nearly 104 million, with more than two million deaths and about 25 million active cases. This has prompted scientists to discover efective drugs to combat this pandemic. Area covered Drug repurposing is the magic bullet for treating severe acute respiratory syndrome coronavirus 2 (SARS￾CoV2). Therefore, several drugs have been investigated in silico, in vitro, as well as through human trials such as anti￾SARS-CoV2 agents, or to prevent the complications resulting from the virus. In this review, the mechanisms of action of diferent therapeutic strategies are summarized. According to the WHO, diferent classes of drugs can be used, including anti-malarial, antiviral, anti-infammatory, and anti-coagulant drugs, as well as angiotensin-converting enzyme inhibitors, antibiotics, vitamins, zinc, neutralizing antibodies, and convalescent plasma therapy. Recently, there are some vaccines which are approved against SARS-CoV2. Expert opinion A complete understanding of the structure and function of all viral proteins that play a fundamental role in viral infection, which contribute to the therapeutic intervention and the development of vaccine in order to reduce the mortality rate.
  • Thumbnail Image
    Item
    Voriconazole Ternary Micellar Systems for the Treatment of Ocular Mycosis: Statistical Optimization and In Vivo Evaluation
    (PlumX Metrics, 12/16/2020) Fahmy, Abdurrahman; Hassan, Mariam; El-Setouhy, Doaa Ahmed; Tayel, Saadia Ahmed; Al-mahallawi, Abdulaziz Mohsen
    Voriconazole (VRC) is a broad spectrum, second generation triazole antifungal. The main use of VRC is via the oral and intravenous route. The study aimed to formulate VRC into ternary micellar systems (TMSs) for the topical treatment of ocular mycosis. TMSs were successfully prepared by water addition/solvent evaporation method, applying a 3-factor D-optimal design. The numerical optimization process suggested an optimal formula (OTMS) composed of total Pluronics to drug weight ratio of 22.89: 1, 1:1 weight ratio of Pluronic® P123 and F68, and 2% w/v of Labrasol. OTMS had high solubilization efficiency of 98.0%, small micellar size of 21.8 nm and suitable zeta potential and polydispersity index values of -9.0 mV and 0.261, respectively. OTMS exhibited acceptable stability for 3 months. Transmission electron microscopy demonstrated the spherical morphology of micelles. OTMS was expected to cause no ocular irritation or blurring in vision as reflected by pH and refractive index measurements. The histopathological study revealed the safety of OTMS for ocular use. The fungal susceptibility testing using Candida albicans demonstrated the superiority of OTMS to VRC suspension, with greater and more durable growth inhibition. Therefore, ocular application of optimized VRC-loaded TMSs can be a promising treatment for ocular mycosis